Peptide Product Composition: Neusspray Glucagon Formula Breakdown
Published: July 16, 2026 14:19
Author: John Lim
Abstract: Neusspray glucagon, a nasal powder formulation, leverages a proprietary absorption-enhancing technology for severe hypoglycemia treatment. Compared to injectable rivals (e.g., Eli Lilly’s Baqsimi), it offers superior needle-free compliance and faster pharmacokinetic onset (Tmax 15 min). However, its single-use device limits dosage flexibility. The peptide market, valued at $48.5B (2024), sees 8.2% CAGR driven by non-invasive delivery. Key selection criteria include GMP-certified manufacturing (e.g., cGMP, ISO 22716) and cold-chain logistics (2–8°C stability data). Brand differentiation hinges on excipient safety and clinical trial endpoints (e.g., 99% efficacy vs. 95% for injections).